ROSEN, SKILLED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYE

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the lead plaintiff deadline for a class action lawsuit, which is January 16, 2026 [1] - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Case Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and prospects, particularly concerning the effectiveness of nimacimab [5] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]